Mulder H, Euser R, Winckers P, Schop C
Anticancer Res. 1985 May-Jun;5(3):321-2.
In a study of 19 patients with breast cancer serum beta 2 microglobulin (beta 2 mu) was evaluated as a tumour marker. Serum beta 2 mu did not correlate with tumour stage, survival time, or histological differentiation grade. Nor did a change of serum beta 2 mu reflect a change of tumour mass. Additionally, serum beta 2 mu lacks specificity and sensitivity, as only 21% of our patients had an increased serum beta 2 mu.
在一项针对19名乳腺癌患者的研究中，血清β2微球蛋白（β2μ）被评估为一种肿瘤标志物。血清β2μ与肿瘤分期、生存时间或组织学分化程度均无关联。血清β2μ的变化也不能反映肿瘤大小的变化。此外，血清β2μ缺乏特异性和敏感性，因为我们的患者中只有21%的血清β2μ升高。
